PDLI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PDLI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. PDL BioPharma's interest expense for the three months ended in Jun. 2020 was $ -0.12 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2020 was $-6.06 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. PDL BioPharma's Operating Income for the three months ended in Jun. 2020 was $ -10.18 Mil. PDL BioPharma's Interest Expense for the three months ended in Jun. 2020 was $ -0.12 Mil. PDL BioPharma did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
The historical data trend for PDL BioPharma's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PDL BioPharma Annual Data | |||||||||||||||||||||
Trend | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | |||||||||||
Interest Expense | Get a 7-Day Free Trial | -27.06 | -18.27 | -20.22 | -12.16 | -11.40 |
PDL BioPharma Quarterly Data | ||||||||||||||||||||
Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | |
Interest Expense | Get a 7-Day Free Trial | -1.17 | -3.01 | -2.45 | -0.47 | -0.12 |
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Jun. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PDL BioPharma (NAS:PDLI) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
PDL BioPharma's Interest Expense for the three months ended in Jun. 2020 was $-0.12 Mil. Its Operating Income for the three months ended in Jun. 2020 was $-10.18 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2020 was $13.51 Mil.
PDL BioPharma's Interest Coverage for the quarter that ended in Jun. 2020 is calculated as
PDL BioPharma did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
David W Gryska | director | 749 N MARY AVE, SUNNYVALE CA 94085 |
John Peter Mclaughlin | director | C/O PDL BIOPHARMA, INC., 932 SOUTHWOOD BOULEVARD, INCLINE VILLAGE NV 89451 |
Dominique Monnet | officer: President and CEO | C/O ALEXION PHARMACEUTICALS, INC., 352 KNOTTER DRIVE, CHESHIRE CT 06410 |
Christopher Lewis Stone | officer: VP, Gen. Counsel & Secretary | 932 SOUTHWOOD BLVD. INCLINE VILLAGE NV 89451 |
Alan Lee Bazaar | director | 9 BEDFORD ROAD, KATONAH NY 10536 |
Natasha Hernday | director | 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451 |
Edward Imbrogno | officer: VP Finance, CAO and Acting CFO | 932 SOUTHWOOD BLVD. INCLINE VILLAGE NV 89451 |
Jill M. Jene | officer: VP, Business Development | 932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451 |
Harold E Selick | director | |
Samuel R Saks | director | 3180 PORTER DRIVE, PALO ALTO CA 94304 |
Paul W Sandman | director | C/O PDL BIOPHARMA, INC., 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451 |
Shlomo Yanai | director | ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073 |
Peter S Garcia | officer: Vice President, CFO | ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010 |
Jody S Lindell | director | 2536 FILLMORE ST., SAN FRANCISCO CA 94115 |
Paul R Edick | director | C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010 |
From GuruFocus
By PRNewswire PRNewswire • 10-02-2020
By PRNewswire PRNewswire • 05-19-2020
By PRNewswire PRNewswire • 12-09-2019
By PRNewswire PRNewswire • 02-25-2020
By PRNewswire PRNewswire • 08-31-2020
By PRNewswire PRNewswire • 03-04-2020
By PRNewswire PRNewswire • 10-30-2019
By [email protected] insider • 02-07-2020
By PRNewswire PRNewswire • 12-10-2019
By PRNewswire PRNewswire • 11-07-2020
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.